Why Venus Concept (VERO) Shares Are Trading Higher Premarket Today? - Venus Concept (NASDAQ:VERO)

Venus Concept Inc VERO has received an FDA 510(k) clearance to market its AI.ME next-generation robotic technology for fractional skin resurfacing.
"We are very pleased to receive the first FDA regulatory clearance for our non-surgical robotic technology platform, AI.ME, and believe it showcases Venus Concept's ongoing investment in technology, innovation, and clinical research towards robotics applications in the field of medical aesthetics," said Rajiv De Silva, CEO.
Related: Venus Concept Taps Endo's Former CEO As New Chief Executive, Withdraws FY22 Guidance.
The AI.ME robotic system utilizes an advanced visualization system, machine vision, and Artificial Intelligence algorithms to target the dermis in a pre-planned selective, and predictable manner.
It uses an array of micro-coring hollow punches to precisely core and excise micro-skin fractions at a precise depth to remove up to 10% of skin in the treatment area, leading to collagen deposition and fractional skin resurfacing of the treated area.
The company looks forward to introducing its first AI.ME systems with Venus Concept's physician partners in 2023.
Price Action: VERO shares are up 81.5% at $0.46 on the last check Wednesday.

Venus Concept Stock Surges On FDA Approval For Robotic Skin Resurfacing Tech